Helicobacter pylori infection in Japan

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 1, 2013, Pages 35-40

  Shiota, Seiji ^a   Murakawi, Kazunari ^a   Suzuki, Rumiko ^a   Fujioka, Toshio ^a   Yamaoka, Yoshio ^a,b  

^a OITA UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

guideline; Helicobacter pylori; Japan; management; resistance; treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CAGA PROTEIN; CLARITHROMYCIN; ESOMEPRAZOLE; GARENOXACIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTEIN DUPA; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; SITAFLOXACIN; TINIDAZOLE; UNCLASSIFIED DRUG; VACUOLATING TOXIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; ENDOSCOPIC SURGERY; HEALTH INSURANCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; JAPAN; MARGINAL ZONE LYMPHOMA; PEPTIC ULCER; PREVALENCE; REVIEW; STOMACH CANCER;

ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; PREVALENCE; PROTON PUMP INHIBITORS; RISK FACTORS; STOMACH NEOPLASMS; STOMACH ULCER; TIME FACTORS; TREATMENT OUTCOME; VIRULENCE;

EID: 84871551768     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.67     Document Type: Review

References (48)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 347(15), 1175-1186 (2002).
2. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 19(3), 449-490 (2006).
3. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 16(Suppl. 1), 1-9 (2011).
4. Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102(3), 760-766 (1992).
5. Shiota S, Murakami K, Fujioka T, Yamaoka Y. Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev. Gastroenterol. Hepatol. 4(2), 149-156 (2010).
6. Take S, Mizuno M, Ishiki K et al. Reinfection rate of Helicobacter pylori after eradication treatment: a long-term prospective study in Japan. J. Gastroenterol. 47(6), 641-646 (2012).
7. Nakajima S, Nishiyama Y, Yamaoka M, Yasuoka T, Cho E. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J. Gastroenterol. Hepatol. 25(Suppl. 1), S99-S110 (2010).
8. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat. Rev. Gastroenterol. Hepatol. 7(11), 629-641 (2010).
9. Shimoyama T, Fukuda S, Tanaka M, Mikami T, Munakata A, Crabtree JE. CagA seropositivity associated with development of gastric cancer in a Japanese population. J. Clin. Pathol. 51(3), 225-228 (1998).
10. Suzuki G, Cullings H, Fujiwara S et al. Low-positive antibody titer against Helicobacter pylori cytotoxin-associated gene A (CagA) may predict future gastric cancer better than simple seropositivity against H. pylori CagA or against H. pylori. Cancer Epidemiol. Biomarkers Prev. 16(6), 1224-1228 (2007).
11. Shiota S, Matsunari O, Watada M, Yamaoka Y. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol. 5(12), 1885-1893 (2010).
12. Vilaichone RK, Mahachai V, Tumwasorn S, Wu JY, Graham DY, Yamaoka Y. Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter 9(5), 453-459 (2004).
13. Yamaoka Y, Kodama T, Kashima K, Graham DY, Sepulveda AR. Variants of the 3' region of the cagA gene in Helicobacter pylori isolates from patients with different H. pylori-associated diseases. J. Clin. Microbiol. 36(8), 2258-2263 (1998).
14. Yamaoka Y, Orito E, Mizokami M et al. Helicobacter pylori in North and South America before Columbus. FEBS Lett. 517(1-3), 180-184 (2002).
15. Matsunari O, Shiota S, Suzuki R et al. Association between Helicobacter pylori virulence factors and gastroduodenal diseases in Okinawa, Japan. J. Clin. Microbiol. 50(3), 876-883 (2012).
16. Truong BX, Mai VT, Tanaka H et al. Diverse characteristics of the CagA gene of Helicobacter pylori strains collected from patients from southern vietnam with gastric cancer and peptic ulcer. J. Clin. Microbiol. 47(12), 4021-4028 (2009).
17. Shiota S, Matsunari O, Yamaoka Y. Relationship between J-Western CagA subtype and the vacA m2 region of Helicobacter pylori. J. Clin. Microbiol. 48(8), 3033-3034 (2010).
18. Xia Y, Yamaoka Y, Zhu Q, Matha I, Gao X. A comprehensive sequence and disease correlation analyses for the C-terminal region of CagA protein of Helicobacter pylori. PLoS One 4(11), e7736 (2009).
19. Suzuki M, Kiga K, Kersulyte D et al. Attenuated CagA oncoprotein in Helicobacter pylori from Amerindians in Peruvian Amazon. J. Biol. Chem. 286(34), 29964-29972 (2011).
20. Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 128(4), 833-848 (2005).
21. Hussein NR. The association of dupA and Helicobacter pylori-related gastroduodenal diseases. Eur. J. Clin. Microbiol. Infect. Dis. 29(7), 817-821 (2010).
22. Shiota S, Matsunari O, Watada M, Hanada K, Yamaoka Y. Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathog. 2(1), 13 (2010).
23. Shiota S, Nguyen LT, Murakami K et al. Association of Helicobacter pylori dupA with the failure of primary eradication. J. Clin. Gastroenterol. 46(4), 297-301 (2012).
24. Takahashi A, Shiota S, Matsunari O et al. Intact long-type dupa as a marker for gastroduodenal diseases in Okinawan subpopulation, Japan. Helicobacter 2012, doi:10.1111/j. 1523-5378. 2012. 00994. x (2012).
25. Kawai M, Furuta Y, Yahara K et al. Evolution in an oncogenic bacterial species with extreme genome plasticity: Helicobacter pylori east Asian genomes. BMC Microbiol. 11, 104 (2011).
26. Fukase K, Kato M, Kikuchi S et al. ; Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372(9636), 392-397 (2008).
27. Ito M, Takata S, Tatsugami M et al. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J. Gastroenterol. 44(5), 365-371 (2009).
28. Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter 15(6), 486-490 (2010).
29. Take S, Mizuno M, Ishiki K et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J. Gastroenterol. 46(3), 318-324 (2011).
30. Nakamura S, Sugiyama T, Matsumoto T et al. ; JAPAN GAST Study Group. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61(4), 507-513 (2012).
31. Asaka M, Kato M, Takahashi S et al. ; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 15(1), 1-20 (2010).
32. Kodama M, Murakami K, Okimoto T et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J. Gastroenterol. 47(4), 394-403 (2012).
33. Kodama M, Murakami K, Okimoto T et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion 85(2), 126-130 (2012).
34. Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol. 45(12), 4006-4010 (2007).
35. Fujioka T, Aoyama N, Sakai K et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. J. Gastroenterol. 47(3), 276-283 (2012).
36. Murakami K, Sato R, Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 17(1), 119-123 (2003).
37. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol. 39(10), 927-930 (2004).
38. Fukuda S, Shimoyama T, Tanaka M, Nakasato F, Fukushi M, Munakata A. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan. Jpn. J. Infect. Dis. 59(6), 367-369 (2006).
39. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J. Clin. Gastroenterol. 42(2), 139-142 (2008).
40. Murakami K, Okimoto T, Kodama M et al. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob. Agents Chemother. 53(7), 3097-3099 (2009).
41. Hirata Y, Ohmae T, Yanai A et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int. J. Antimicrob. Agents 39(4), 352-355 (2012).
42. Matsuzaki J, Suzuki H, Nishizawa T et al. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first-and second-line therapies. Antimicrob. Agents Chemother. 56(3), 1643-1645 (2012).
43. Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. 146(8), 556-563 (2007).
44. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 56(10), 1353-1357 (2007).
45. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA 300(11), 1346-1347 (2008).
46. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol. 104(12), 3069-3079; quiz 1080 (2009).
47. Nakajima S, Inoue H, Inoue T, Maruoka Y. Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. J. Gastroenterol. Hepatol. 27(Suppl. 3), 108-111 (2012).
48. Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin. Exp. Gastroenterol. 5, 49-59 (2012).